The MPT Product Development Database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes. Click on the product name to access detailed information on each product.

Inclusion Criteria

Product Classification

For a product to be classified as an MPT, the MPT Product Development Database requires that it demonstrates, through preclinical or clinical studies, successful positive test results for two or more of the following indications: unintended pregnancy, HIV and/or other STIs, and an initiated IND filing process with the FDA.

Development Stages

Advanced technologies in Preclinical (P2) and Clinical (C1-C3) stages of product development are required to meet one or more of the following criteria:

1) GMP manufactured drug or device
2) Initiation of IND enabling preclinical GLP toxicology studies program
3) In vivo animal model data supporting an MPT target indication

For an MPT product in development for more than one indication, the listed Stage of Development will be based on the earliest stage of development for an individual indications listed for that product. For example, a product in a phase 3 efficacy trial for contraception and in preclinical development for STI prevention would be categorized as pre-clinical as an MPT. More detailed information on development stages for each product and each indication is listed in the detailed product profile and can be accessed by clicking on the product name.
Database Update Methodology

The MPT Product Development Database will undergo a bi-annual update using resources vetted for this purpose, including:

1) Publically available search mechanisms for MPT relevant funding provided by foundations and government agencies,
2) Review of published peer-reviewed literature,
3) Review of published materials from relevant scientific conferences and stakeholder meetings,
4) Information provided by the IMPT and Network of Experts (NoE) members about latest scientific developments in the areas of contraception and HIV prevention,
5) Information from industry and other relevant stakeholders, and
6) Field relevant online resources.

After each round of fielding new data and preparing new information for the MPT database, the database updates will be regularly reviewed and vetted by experts of the IMPT Scientific Agenda Working Group (SAWG) and other members of the Initiative. To this end, the online database includes a feedback form for users to report on missing and/or incorrect information in the database.

In addition, CAMI Health staff is in regular contact with developer stakeholders and collects and incorporates and feedback they have related to their products on an ongoing basis in an effort to ensure the information included in the database remains as up to date as possible. In the future, CAMI Health will also undertake regular efforts to track the developments in related areas, such as MPT-related manufacturing and drug delivery technologies.

If you know of an MPT product not included in the database or have updated information for listed products, please contact us at cami@cami-health.org.